Cytokinetics' Myqorzo: The Challenger Drug Poised to Reshape a Multi-Billion Dollar Heart Market

Related Articles

What Makes Cytokinetics' MYQORZO Launch a Game Changer

6 months ago

Is the FDA Poised to Reshape the Peptide Market

5 months ago

Why is Laurus Investment Counsel Making a Multi-Billion Dollar Bet on Microsoft

5 months ago

AMD's Anthropic Bet: A Multi-Billion-Dollar Validation with a Valuation Catch

1 months ago

Category

You may also like

Stock News•6 days ago

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan holds $660.7M in liquid assets, funding 2–3 years of runway for three precision cardiology programs targeting genetic DCM, moderate CAVS, and post-hospitalization ASH. Pivotal 2027 readouts w...

KARD

Share

News•1 week ago

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness

Big Pharma's cardiovascular drug business is losing profitability as heart disease, the top global killer, becomes harder to monetize. The shift pressures drugmakers and Wall Street as revenue growth ...

Share

Stock News•3 weeks ago

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics' aficamten significantly improved symptoms and exercise capacity in late-stage data for patients with a genetic heart condition lacking approved treatments, potentially expanding the drug...

CYTK

Share